RU2000111506A - PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASE - Google Patents
PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASEInfo
- Publication number
- RU2000111506A RU2000111506A RU2000111506/14A RU2000111506A RU2000111506A RU 2000111506 A RU2000111506 A RU 2000111506A RU 2000111506/14 A RU2000111506/14 A RU 2000111506/14A RU 2000111506 A RU2000111506 A RU 2000111506A RU 2000111506 A RU2000111506 A RU 2000111506A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- cps
- usp
- parkinson
- Prior art date
Links
- 206010061536 Parkinson's disease Diseases 0.000 title claims 6
- 230000002035 prolonged Effects 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 6
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 claims 5
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 229920002261 Corn starch Polymers 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 3
- 239000008120 corn starch Substances 0.000 claims 3
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
Claims (1)
(a)(R)-5,6-дигидро-5-(метиламино)-4Н-имидазо [4,5-ij)] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) 0,3%-16%
(b) крахмал 60%-69%
(c) гидроксипропилметилцеллюлозу 30%-40%
2. Фармацевтическая композиция по п. 1, которая включает
(a) (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо [4,5-ij)] -хинолин-2(1Н)-он(Z)-2-бутендиоат (1: 1) 0,44%-10%
(b) преклейстеризованный или кукурузный крахмал 60%-67%
(c) гидроксипропилметилцеллюлозу 30%-40%
3. Фармацевтическая композиция по п. 1, в которой (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо[4,5-ij] ] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) присутствует в количестве от около 0,3% (1 мг) до около 16% (56 мг)/таблетку.1. The pharmaceutical composition, which is a tablet with a prolonged release for oral administration, which contains
(a) (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij)] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1 ) 0.3% -16%
(b) starch 60% -69%
(c) hydroxypropyl methyl cellulose 30% -40%
2. The pharmaceutical composition according to claim 1, which includes
(a) (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij)] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1 ) 0.44% -10%
(b) pre-pasteurized or corn starch 60% -67%
(c) hydroxypropyl methyl cellulose 30% -40%
3. The pharmaceutical composition according to claim 1, in which (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij]] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1) is present in an amount of about 0.3% (1 mg) to about 16% (56 mg) / tablet.
гидроксипропилметилцеллюлозу 2208 USP 100 сПз,
гидроксипропилметилцеллюлозу 2208 USP 4000 сПз,
гидроксипропилметилцеллюлозу 2208 USP 15000 сПз,
гидроксипропилметилцеллюлозу 2208 USP 100000 сПз,
гидроксипропилметилцеллюлозу 2910 USP 4000 сПз,
гидроксипропилметилцеллюлозу 2910 USP 10000 сПз
или их смеси.7. The pharmaceutical composition according to claim 1, in which hydroxypropylmethyl cellulose is selected from the group including:
hydroxypropyl methylcellulose 2208 USP 100 cps,
hydroxypropyl methylcellulose 2208 USP 4000 cps,
hydroxypropyl methylcellulose 2208 USP 15,000 cps,
hydroxypropyl methylcellulose 2208 USP 100,000 cps,
hydroxypropyl methylcellulose 2910 USP 4000 cps,
hydroxypropyl methylcellulose 2910 USP 10,000 cps
or mixtures thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6082797P | 1997-09-30 | 1997-09-30 | |
US60/060,827 | 1997-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000111506A true RU2000111506A (en) | 2002-05-10 |
RU2205007C2 RU2205007C2 (en) | 2003-05-27 |
Family
ID=22031996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000111506/14A RU2205007C2 (en) | 1997-09-30 | 1998-09-03 | Sustained-release tablets for parkinson's disease treatment |
Country Status (23)
Country | Link |
---|---|
US (2) | US6197339B1 (en) |
EP (1) | EP1017391B1 (en) |
JP (1) | JP2001517701A (en) |
KR (1) | KR100516095B1 (en) |
CN (1) | CN1195518C (en) |
AT (1) | ATE297208T1 (en) |
AU (1) | AU742941B2 (en) |
BR (1) | BR9812687A (en) |
CA (1) | CA2301869A1 (en) |
DE (1) | DE69830503T2 (en) |
DK (1) | DK1017391T3 (en) |
ES (1) | ES2242296T3 (en) |
FI (1) | FI20000720A (en) |
HK (1) | HK1030163A1 (en) |
HU (1) | HUP0004586A2 (en) |
NO (1) | NO320303B1 (en) |
NZ (1) | NZ504221A (en) |
PL (1) | PL191125B1 (en) |
PT (1) | PT1017391E (en) |
RU (1) | RU2205007C2 (en) |
SI (1) | SI1017391T1 (en) |
SK (1) | SK3612000A3 (en) |
WO (1) | WO1999016442A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2358865A1 (en) | 1999-02-05 | 2000-08-10 | Pharmacia & Upjohn Company | Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one |
US6667060B1 (en) | 1999-03-31 | 2003-12-23 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
AR031152A1 (en) * | 2000-10-31 | 2003-09-10 | Upjohn Co | NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME |
FR2825705B1 (en) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS |
US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
ATE480235T1 (en) * | 2001-12-11 | 2010-09-15 | Univ Virginia | USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLERosis |
FR2835186B1 (en) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
US20030203055A1 (en) * | 2002-03-15 | 2003-10-30 | Cypress Bioscience, Inc. | Methods of treating visceral pain syndromes |
US20050079217A1 (en) * | 2002-07-25 | 2005-04-14 | Ganorkar Loksidh D. | Sustained-release tablet composition comprising a dopamine receptor agonist |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
AR040682A1 (en) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
FR2844273B1 (en) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS. |
MXPA05003513A (en) * | 2002-10-04 | 2005-06-03 | Pharmacia Corp | Pharmaceutical compositions for treatment of parkinson's disease. |
CA2500919A1 (en) * | 2002-10-04 | 2004-04-22 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
CN1728998A (en) * | 2002-10-25 | 2006-02-01 | 法玛西雅厄普约翰有限责任公司 | Use of heterocyclic amine-type compounds as neuroprotective agents |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
WO2004067039A1 (en) * | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
JP4971159B2 (en) * | 2004-08-13 | 2012-07-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use |
CN101849921A (en) * | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | The prolongation release tablet that comprises pramipexole or its officinal salt |
JP2009504748A (en) * | 2005-08-15 | 2009-02-05 | ユニバーシティ オブ バージニア パテント ファウンデーション | Nerve recovery with R (+) pramipexole |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
CA2641665A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
KR20090021169A (en) | 2006-05-16 | 2009-02-27 | 크놉 뉴로사이언시스 인코포레이티드 | Compositions of r(+) and s(-) pramipexole and methods of using the same |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP2334185A4 (en) * | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | Compositions and methods of using (r)-pramipexole |
CA2845147A1 (en) | 2011-09-23 | 2013-03-28 | Roche Glycart Ag | Bispecific anti-egfr/anti igf-1r antibodies |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
PL3019167T3 (en) | 2013-07-12 | 2021-06-14 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
ES2813674T3 (en) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
HUE055850T2 (en) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
CA2051697C (en) * | 1989-06-09 | 1996-10-08 | Malcolm Wilson Moon | Heterocyclic amines having central nervous system activity |
US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
US5000962A (en) | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
GB9605857D0 (en) | 1996-03-20 | 1996-05-22 | Tester Richard F | Polysaccharides as chemical release systems |
CA2173818A1 (en) | 1996-04-10 | 1997-10-11 | Francois Chouinard | Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose |
-
1998
- 1998-03-09 US US09/146,090 patent/US6197339B1/en not_active Expired - Fee Related
- 1998-09-03 CA CA002301869A patent/CA2301869A1/en not_active Abandoned
- 1998-09-03 PT PT98945805T patent/PT1017391E/en unknown
- 1998-09-03 KR KR10-2000-7003349A patent/KR100516095B1/en not_active IP Right Cessation
- 1998-09-03 ES ES98945805T patent/ES2242296T3/en not_active Expired - Lifetime
- 1998-09-03 NZ NZ504221A patent/NZ504221A/en unknown
- 1998-09-03 RU RU2000111506/14A patent/RU2205007C2/en not_active IP Right Cessation
- 1998-09-03 AU AU92964/98A patent/AU742941B2/en not_active Ceased
- 1998-09-03 DK DK98945805T patent/DK1017391T3/en active
- 1998-09-03 JP JP2000513578A patent/JP2001517701A/en not_active Withdrawn
- 1998-09-03 CN CNB988087170A patent/CN1195518C/en not_active Expired - Fee Related
- 1998-09-03 BR BR9812687-3A patent/BR9812687A/en not_active Application Discontinuation
- 1998-09-03 AT AT98945805T patent/ATE297208T1/en not_active IP Right Cessation
- 1998-09-03 HU HU0004586A patent/HUP0004586A2/en unknown
- 1998-09-03 WO PCT/US1998/017992 patent/WO1999016442A2/en active IP Right Grant
- 1998-09-03 EP EP98945805A patent/EP1017391B1/en not_active Expired - Lifetime
- 1998-09-03 PL PL339946A patent/PL191125B1/en not_active IP Right Cessation
- 1998-09-03 SI SI9830770T patent/SI1017391T1/en unknown
- 1998-09-03 DE DE69830503T patent/DE69830503T2/en not_active Expired - Fee Related
- 1998-09-03 SK SK361-2000A patent/SK3612000A3/en unknown
-
2000
- 2000-03-29 NO NO20001624A patent/NO320303B1/en unknown
- 2000-03-29 FI FI20000720A patent/FI20000720A/en unknown
-
2001
- 2001-01-11 US US09/759,286 patent/US20010053386A1/en not_active Abandoned
- 2001-02-21 HK HK01101251A patent/HK1030163A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000111506A (en) | PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
CA2257431C (en) | Fast-dissolving galanthamine hydrobromide tablet | |
US4309405A (en) | Sustained release pharmaceutical compositions | |
US4309406A (en) | Sustained release pharmaceutical compositions | |
CA1147651A (en) | Sustained release pharmaceutical compositions | |
HUP0004586A2 (en) | Sustained release tablet formulation to treat parkinson disease | |
TW576743B (en) | Extended release formulations of erythromycin derivatives | |
AU705488B2 (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
CA2289260C (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
CA2601289A1 (en) | Once-a-day oxycodone formulations | |
AU5405094A (en) | Stable extended release oral dosage composition | |
KR20110028326A (en) | Stable extended release oral dosage composition | |
JP2002528408A (en) | Controlled release pharmaceutical formulation containing cGMPPDE-5 inhibitor | |
JP2003531165A (en) | Composition | |
JP2003519181A (en) | Methods and formulations for treating resistance to antihypertensives and related conditions | |
JP5561885B2 (en) | A new formulation of mirtazapine | |
JP2002543128A (en) | Treatment of female arousal disorder | |
JPH04210924A (en) | Pharmaceutical composition for oral admini- stration of calcitonin and its dosage form | |
NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
CA2180703A1 (en) | Fast-dissolving galanthamine hydrobromide tablet | |
NZ535261A (en) | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide | |
US20040192706A1 (en) | Method and compositions for treating anxiety | |
WO1995033451A1 (en) | Non-sedating allergy sinus medication | |
WO1996026722A1 (en) | Use of isosorbide-5-mononitrate | |
MXPA97006492A (en) | Use of isosorb 5-mononitrate |